APGE · NASDAQ · STOCK
Apogee Therapeutics (APGE) Stock Analysis
$135.08
52W $35.39 – $135.09
57/100
$8.40B
-31.1
0.34
Is APGE Bullish or Bearish?
Mixed.
Innellis AI committee rates Apogee Therapeutics, Inc. (APGE) Watch with a composite score of 57/100
, based on 6 analysts with 50% agreement.
Last updated September 07, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +2.60 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -17.40 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — growth rate is decelerating quarter over quarter -- the trend line matters more than the level. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.17 across 6 articles, 14d) — News
Bear Case
- ROE of only -29.9% -- cheap may mean cheap for a reason — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 82 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 90 -- overbought on the larger timeframe too — Technical
- Negative filing: Termination of a material agreement, Delisting notice or failure to satisfy listing rule (3d ago) — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 07, 2026
Overall Committee Score
57/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 49%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -29.9% -- cheap may mean cheap for a reason
Growth Analyst
bearish
35
/ 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 82 is in overbought territory
Risk Analyst
bullish
75
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
49
/ 100 · Moderate confidence
News flow is mixed or quiet -- no strong signal either way right now
+ News sentiment is positive (+0.17 across 6 articles, 14d)
− Negative filing: Termination of a material agreement, Delisting notice or failure to satisfy listing rule (3d ago)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score moved marginally from 57.4 to 57.4.
Comparing 2026-09-06 to 2026-09-07 (1 day apart).
Technical Analysis
RSI (14)
81.8
Overbought
MACD Histogram
-0.392
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
0.91
Inside Bands
Price vs Moving Averages
EMA 9
$134.95
Above
EMA 21
$134.39
Above
EMA 50
$128.05
Above
EMA 200
$96.54
Above
Fundamental Analysis
Valuation
33
Growth
53
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-31.1×
P/B Ratio
8.53×
PEG Ratio
6.57
Dividend Yield
0.00%
52W High
$135.09
52W Low
$35.39
Quality & Growth
ROE
-2830.5%
ROA
-2730.1%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.01
AI Fundamental Assessment
P/E ratio of -31.1 (inexpensive relative to a 15-40x range); Price-to-book of 8.5x; PEG ratio of 6.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -28.3%; Return on assets of -27.3%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 26.44 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is negative (-3.23); Most recent quarter missed estimates by 4.4%; EPS growth decelerating (-2.9% -> -7.5% QoQ); Analyst estimates rising over recent quarters
Get the Full APGE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →